APA

Reinshagen M., Schütz E., Armstrong V. W., Behrens C., von Tirpitz C., Stallmach A., Herfarth H., Stein J., Bias P., Adler G., Shipkova M., Kruis W., Oellerich M. & von Ahsen N. (20070918). 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. : Clinical chemistry.

Chicago

Reinshagen Max, Schütz Ekkehard, Armstrong Victor W, Behrens Christoph, von Tirpitz Christian, Stallmach Andreas, Herfarth Hans, Stein Jürgen, Bias Peter, Adler Guido, Shipkova Maria, Kruis Wolfgang, Oellerich Michael and von Ahsen Nicolas. 20070918. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. : Clinical chemistry.

Harvard

Reinshagen M., Schütz E., Armstrong V. W., Behrens C., von Tirpitz C., Stallmach A., Herfarth H., Stein J., Bias P., Adler G., Shipkova M., Kruis W., Oellerich M. and von Ahsen N. (20070918). 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. : Clinical chemistry.

MLA

Reinshagen Max, Schütz Ekkehard, Armstrong Victor W, Behrens Christoph, von Tirpitz Christian, Stallmach Andreas, Herfarth Hans, Stein Jürgen, Bias Peter, Adler Guido, Shipkova Maria, Kruis Wolfgang, Oellerich Michael and von Ahsen Nicolas. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. : Clinical chemistry. 20070918.